TB vaccine strategies-What is needed to solve a complex problem?

Tuberculosis

Volumn 86, Issue 3-4 SPEC. ISS., 2006, Pages 163-168

  Dietrich, Jes ^a   Vingsbo Lundberg, Carina ^a   Andersen, Peter ^a  

^a STATENS SERUM INSTITUT   (Denmark)

Author keywords

Bacterial; BCG; Latency; Tuberculosis; Vaccination

Indexed keywords

AG85B ESAT 6 FUSION PROTEIN; AG85B TB10.4 FUSION PROTEIN; BCG VACCINE; CULTURE FILTRATE PROTEIN 10; DNA VACCINE; EARLY SECRETORY ANTIGENIC TARGET 6; GENE PRODUCT; LISTERIOLYSIN; LISTERIOLYSIN O; LIVE VACCINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PROTEIN AG85A; PROTEIN AG85B; PROTEIN MTB72F; RECOMBINANT VACCINE; RV 2031C ANTIGEN; SUBUNIT VACCINE; TB10.4 ANTIGEN; UNCLASSIFIED DRUG; VIRUS VECTOR;

ANTIGEN SPECIFICITY; ARTICLE; BCG VACCINATION; CLINICAL TRIAL; DRUG DESIGN; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; EXPRESSION VECTOR; GENE CONSTRUCT; GENE OVEREXPRESSION; GENE TARGETING; HUMAN; IMMUNE RESPONSE; INFECTION PREVENTION; LATENT PERIOD; LISTERIA MONOCYTOGENES; MYCOBACTERIUM TUBERCULOSIS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REINFECTION; TUBERCULOSIS; VACCINE PRODUCTION; VIRAL GENE DELIVERY SYSTEM;

HUMANS; MYCOBACTERIUM BOVIS; TUBERCULOSIS; TUBERCULOSIS VACCINES; VACCINATION; VACCINES, SUBUNIT;

EID: 33646179026     PISSN: 14729792     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tube.2006.01.009     Document Type: Article

References (58)

1. WHO. Global tuberculosis control-suirveillance, planning, financing, World Health Organisation, Geneva, Switzerland, 2005.
2. Dolin Pj R.M., and Kochi A. Global tuberculosis incidence and mortality during 1990-2000. Bull World Health Organ 72 (1994) 213-220
3. Boon C., and Dick T. Mycobacterium bovis BCG response regulator essential for hypoxic dormancy. J Bacteriol 184 (2002) 6760-6767
4. Voskuil M.I., Schnappinger D., Visconti K.C., Harrell M.I., Dolganov G.M., Sherman D.R., et al. Inhibition of respiration by nitric oxide induces a Mycobacterium tuberculosis dormancy program. J Exp Med 198 (2003) 705-713
5. Sherman D.R., Voskuil M., Schnappinger D., Liao R., Harrell M.I., and Schoolnik G.K. Regulation of the Mycobacterium tuberculosis hypoxic response gene encoding alpha -crystallin. Proc Natl Acad Sci U S A 98 (2001) 7534-7539
6. al-Kassimi F.A., al-Hajjaj M.S., al-Orainey I.O., and Bamgboye E.A. Does the protective effect of neonatal BCG correlate with vaccine-induced tuberculin reaction. Does the protective effect of neonatal BCG correlate with vaccine-induced tuberculin reaction. Am J Respir Crit Care Med 152 (1995) 1575-1578
7. Sterne J.A., Rodrigues L.C., and Guedes I.N. Does the efficacy of BCG decline with time since vaccination?. Int J Tuberc Lung Dis 2 (1998) 200-207
8. Lanckriet C., Levy-Bruhl D., Bingono E., Siopathis R.M., and Guerin N. Efficacy of BCG vaccination of the newborn: evaluation by a follow-up study of contacts in Bangui. Int J Epidemiol 24 (1995) 1042-1049
9. Colditz G.A., Berkey C.S., Mosteller F., Brewer T.F., Wilson M.E., Burdick E., et al. The efficacy of bacillus Calmette-Guerin vaccination of newborns and infants in the prevention of tuberculosis: meta-analyses of the published literature. Pediatrics 96 (1995) 29-35
10. Brewer T.F. Preventing tuberculosis with bacillus Calmette-Guerin vaccine: a meta-analysis of the literature. Clin Infect Dis 31 Suppl 3 (2000) S64-S67
11. Fine P.E. Variation in protection by BCG: implications of and for heterologous immunity. Lancet 346 (1995) 1339-1345
12. Colditz G.A., Brewer T.F., Berkey C.S., Wilson M.E., Burdick E., Fineberg H.V., et al. Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature [see comments]. JAMA 271 (1994) 698-702
13. Hart P.D., and Sutherland I. BCG and vole bacillus vaccines in the prevention of tuberculosis in adolescence and early adult life. Br Med J 2 (1977) 293-295
14. Comstock G.W., Woolpert S.F., and Livesay V.T. Tuberculosis studies in Muscogee County, Gerorgia. Twent-year evaluation of community trial of BCG vaccination. Public Health Rep 91 (1976) 276-280
15. Brandt L., Feino Cunha J., Weinreich Olsen A., Chilima B., Hirsch P., Appelberg R., et al. Failure of the Mycobacterium bovis BCG vaccine: some species of environmental mycobacteria block multiplication of BCG and induction of protective immunity to tuberculosis. Infect Immun 70 (2002) 672-678
16. Pym A.S., Brodin P., Majlessi L., Brosch R., Demangel C., Williams A., et al. Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis. Nat Med 9 (2003) 533-539
17. Horwitz M.A., Harth G., Dillon B.J., and Maslesa-Galic S. Recombinant bacillus calmette-guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model. Proc Natl Acad Sci USA 97 (2000) 13853-13858
18. Grode L., Seiler P., Baumann S., Hess J., Brinkmann V., Eddine A.N., et al. Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guerin mutants that secrete listeriolysin. J Clin Invest 115 (2005) 2472-2479
19. Hesseling A.C., Schaaf H.S., Hanekom W.A., Beyers N., Cotton M.F., Gie R.P., et al. Danish bacille Calmette-Guerin vaccine-induced disease in human immunodeficiency virus-infected children. Clin Infect Dis 37 (2003) 1226-1233
20. Hesseling A.C., Schaaf H.S., Victor T., Beyers N., Marais B.J., Cotton M.F., et al. Resistant Mycobacterium bovis Bacillus Calmette-Guerin disease: implications for management of Bacillus Calmette-Guerin Disease in human immunodeficiency virus-infected children. Pediatr Infect Dis J 23 (2004) 476-479
21. Andersen P., and Doherty T.M. TB subunit vaccines-putting the pieces together. Microbes Infect 7 (2005) 911-921
22. Orme I.M. The immune response to the cell wall of Mycobacterium bovis BCG. Clin Exp Immunol 71 (1988) 388-393
23. Andersen P., Askgaard D., Ljungqvist L., Bentzon M.W., and Heron I. T-cell proliferative response to antigens secreted by Mycobacterium tuberculosis. Infect Immun 59 (1991) 1558-1563
24. Hubbard R.D., Flory C.M., and Collins F.M. Immunization of mice with mycobacterial culture filtrate proteins. Clin Exp Immunol 87 (1992) 94-98
25. Pal P.G., and Horwitz M.A. Immunization with extracellular proteins of Mycobacterium tuberculosis induces cell-mediated immune responses and substantial protective immunity in a guinea pig model of pulmonary tuberculosis. Infect Immun 60 (1992) 4781-4792
26. Andersen P. The T cell response to secreted antigens of Mycobacterium tuberculosis. Immunobiology 191 (1994) 537-547
27. Andersen P., Askgaard D., Gottschau A., Bennedsen J., Nagai S., and Heron I. Identification of immunodominant antigens during infection with Mycobacterium tuberculosis. Scand J Immunol 36 (1992) 823-831
28. Boesen H., Jensen B.N., Wilcke T., and Andersen P. Human T-cell responses to secreted antigen fractions of Mycobacterium tuberculosis. Infect Immun 63 (1995) 1491-1497
29. Kamath A.T., Feng C.G., Macdonald M., Briscoe H., and Britton W.J. Differential protective efficacy of DNA vaccines expressing secreted proteins of Mycobacterium tuberculosis. Infect Immun 67 (1999) 1702-1707
30. Li Z., Howard A., Kelley C., Delogu G., Collins F., and Morris S. Immunogenicity of DNA vaccines expressing tuberculosis proteins fused to tissue plasminogen activator signal sequences. Infect Immun 67 (1999) 4780-4786
31. Brandt L., Elhay M., Rosenkrands I., Lindblad E.B., and Andersen P. ESAT-6 subunit vaccination against Mycobacterium tuberculosis. Infect Immun 68 (2000) 791-795
32. Dietrich J., Aagaard C., Leah R., Olsen A.W., Stryhn A., Doherty T.M., et al. Exchanging ESAT6 with TB10.4 in an Ag85B fusion molecule-based tuberculosis subunit vaccine: efficient protection and ESAT6-based sensitive monitoring of vaccine efficacy. J Immunol 174 (2005) 6332-6339
33. Silver R.F., Wallis R.S., and Ellner J.J. Mapping of T cell epitopes of the 30-kDa alpha antigen of Mycobacterium bovis strain bacillus Calmette-Guerin in purified protein derivative (PPD)-positive individuals. J Immunol 154 (1995) 4665-4674
34. Mustafa A.S., Shaban F.A., Abal A.T., Al-Attiyah R., Wiker H.G., Lundin K.E., et al. Identification and HLA restriction of naturally derived Th1-cell epitopes from the secreted Mycobacterium tuberculosis antigen 85B recognized by antigen-specific human CD4(+) T-cell lines. Infect Immun 68 (2000) 3933-3940
35. Roche P.W., Peake P.W., Billman-Jacobe H., Doran T., and Britton W.J. T-cell determinants and antibody binding sites on the major mycobacterial secretory protein MPB59 of Mycobacterium bovis. Infect Immun 62 (1994) 5319-5326
36. Feng C.G., Palendira U., Demangel C., Spratt J.M., Malin A.S., and Britton W.J. Priming by DNA immunization augments protective efficacy of Mycobacterium bovis Bacille Calmette-Guerin against tuberculosis. Infect Immun 69 (2001) 4174-4176
37. Huygen K., Content J., Denis O., Montgomery D.L., Yawman A.M., Deck R.R., et al. Immunogenecity and protective efficacy of a tuberculosis DNA vaccine. Nat Med 2 (1996) 893-898
38. Lozes E., Huygen K., Content J., Denis O., Montgomery D.L., Yawman A.M., et al. Immunogenicity and efficacy of a tuberculosis DNA vaccine encoding the components of the secreted antigen 85 complex. Vaccine 15 (1997) 830-833
39. Olsen A.W., Williams A., Okkels L.M., Hatch G., and Andersen P. Protective effect of a tuberculosis subunit vaccine based on a fusion of antigen 85B and ESAT-6 in the aerosol guinea pig model. Infect Immun 72 (2004) 6148-6150
40. Olsen A.W., van Pinxteren L.A., Okkels L.M., Rasmussen P.B., and Andersen P. Protection of mice with a tuberculosis subunit vaccine based on a fusion protein of antigen 85b and esat-6. Infect Immun 69 (2001) 2773-2778
41. Langermans J.A., Doherty T.M., Vervenne R.A., van der Laan T., Lyashchenko K., Greenwald R., et al. Protection of macaques against Mycobacterium tuberculosis infection by a subunit vaccine based on a fusion protein of antigen 85B and ESAT-6. Vaccine 23 (2005) 2740-2750
42. Palendira U., Spratt J.M., Britton W.J., and Triccas J.A. Expanding the antigenic repertoire of BCG improves protective efficacy against aerosol Mycobacterium tuberculosis infection. Vaccine 23 (2005) 1680-1685
43. Brock I., Weldingh K., Leyten E.M., Arend S.M., Ravn P., and Andersen P. Specific T-cell epitopes for immunoassay-based diagnosis of Mycobacterium tuberculosis infection. J Clin Microbiol 42 (2004) 2379-2387
44. Lalvani A., Pathan A.A., McShane H., Wilkinson R.J., Latif M., Conlon C.P., et al. Rapid detection of Mycobacterium tuberculosis infection by enumeration of antigen-specific T cells. Am J Respir Crit Care Med 163 (2001) 824-828
45. Ravn P., Demissie A., Eguale T., Wondwosson H., Lein D., Amoudy H., et al. Human T cell responses to the ESAT-6 antigen from Mycobacterium tuberculosis. J Infect Dis 179 (1999) 637-645
46. Skjot R.L., Oettinger T., Rosenkrands I., Ravn P., Brock I., Jacobsen S., et al. Comparative evaluation of low-molecular-mass proteins from Mycobacterium tuberculosis identifies members of the ESAT-6 family as immunodominant T-cell antigens. Infect Immun 68 (2000) 214-220
47. Skjot R.L., Brock I., Arend S.M., Munk M.E., Theisen M., Ottenhoff T.H., et al. Epitope mapping of the immunodominant antigen TB10.4 and the two homologous proteins TB10.3 and TB12.9, which constitute a subfamily of the esat-6 gene family. Infect Immun 70 (2002) 5446-5453
48. Derrick S.C., Yang A.L., and Morris S.L. A polyvalent DNA vaccine expressing an ESAT6-Ag85B fusion protein protects mice against a primary infection with Mycobacterium tuberculosis and boosts BCG-induced protective immunity. Vaccine 23 (2004) 780-788
49. McShane H., Pathan A.A., Sander C.R., Keating S.M., Gilbert S.C., Huygen K., et al. Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nat Med 10 (2004) 1240-1244
50. Brandt L., Skeiky Y.A., Alderson M.R., Lobet Y., Dalemans W., Turner O.C., et al. The protective effect of the Mycobacterium bovis BCG vaccine is increased by coadministration with the Mycobacterium tuberculosis 72-kilodalton fusion polyprotein Mtb72F in M. tuberculosis-infected guinea pigs. Infect Immun 72 (2004) 6622-6632
51. In: Voskuil M.I., Visconti K.C., and Schoolnik G.K. (Eds). Mycobacterium tuberculosis gene expression during adaptation to stationary phase and low-oxygen dormancy. Tuberculosis (Edinb) 84 (2004) 218-227
52. Cunningham A.F., and Spreadbury C.L. Mycobacterial stationary phase induced by low oxygen tension: cell wall thickening and localization of the 16-kilodalton alpha-crystallin homolog. J Bacteriol 180 (1998) 801-808
53. Yuan Y., Crane D.D., and Barry III C.E. Stationary phase-associated protein expression in Mycobacterium tuberculosis: function of the mycobacterial alpha-crystallin homolog. J Bacteriol 178 (1996) 4484-4492
54. Schnappinger D., Ehrt S., Voskuil M.I., Liu Y., Mangan J.A., Monahan I.M., et al. Transcriptional adaptation of Mycobacterium tuberculosis within macrophages: insights into the phagosomal environment. J Exp Med 198 (2003) 693-704
55. Purkayastha A., McCue L.A., and McDonough K.A. Identification of a Mycobacterium tuberculosis putative classical nitroreductase gene whose expression is coregulated with that of the acr aene within macrophages, in standing versus shaking cultures, and under low oxygen conditions. Infect Immun 70 (2002) 1518-1529
56. Yuan Y., Crane D.D., Simpson R.M., Zhu Y.Q., Hickey M.J., Sherman D.R., et al. The 16-kDa alpha-crystallin (Acr) protein of Mycobacterium tuberculosis is required for growth in macrophages. Proc Natl Acad Sci USA 95 (1998) 9578-9583
57. In: Muttucumaru D.G., Roberts G., Hinds J., Stabler R.A., and Parish T. (Eds). Gene expression profile of Mycobacterium tuberculosis in a non-replicating state. Tuberculosis (Edinb) 84 (2004) 239-246
58. Demissie A, Leyten EM, Abebe M, Wassie L, Aseffa A, Abate G, Fletcher H, Owiafe P, Hill PC, Brookes R, Rook G, Zumla A, Arend SM, Klein M, Ottenhoff TH, Andersen P, Doherty TM, the VACSEL Study Group. Recognition of stage-specific mycobacterial antigens differentiates between acute and latent infections with Mycobacterium tuberculosis. Clin Vaccine Immunol. 2006; 13: 179-86.